POLYPHARMACY IN THE ELDERLY PEOPLE – A REVIEW

Shreeraam.J[1], Syed Fadil Mohammed [1], Praveen.D[2], Ranadheer.P[2], Vijey Aanandhi.M[3]

[1]School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS), Chennai, India.

[2]Research Scholar, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS), Chennai, India

[3]Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS), Chennai, India.

Corresponding Author

Dr. M. Vijey Aanandhi

Professor and Head,

Department of Pharmaceutical Chemistry and Analysis,

School of Pharmaceutical Sciences,

Vels Institute of Science Technology and Advanced Studies (VISTAS),

Pallavaram, Chennai – 600117, India.

ABSTRACT

Medications to give disease and extend life in our patients often gather in amounts, causing in what has been named “polypharmacy.” This inexact label usually designates the addition of more medications. Polypharmacy in proceeding age frequently results in drug therapy difficulties related to dealings, drug poisonousness, and falls with injury, and non-adherence. Polypharmacy is linked with causing increased hospitalizations and difficult costs of care for entities and health care systems. To reduce polypharmacy, we explain a systematic, review approach to find highest-risk medications and drug-therapy problems. We lecture calculated reductions (deprescribing) of medicines in palliative care, long-term care, and older adults. Polypharmacy is an growing concern as fresher patients attain ailments, such as diabetes, necessitating health management.Polypharmacy is collective and recurrently shows relations with problems such as falls, hospitalizations, and death, regardless of which medicines are involved. The request of guidelines such as Beers and STOPP/START criteria distinguish high-risk medicines in elderly adults and are exposed to stop ADEs and complete health care costs.More often, prescribers are seeing replacements to prescribing medicines that grasp higher dangers in old patients.

Keywords- Polypharmacy, Review, Elderly

INTRODUCTION

Taking numerous medications is insideguidelines for management of hypertension, diabetes, and heart failure for attainment of management goals. Extra patient comorbidities interpret to attendantmedications, which may effect in a "prescribing cascade." This happens with medicines being additional to pleasure or stopside effects of other medicines. Polypharmacy is an growing concern as fresher patients attainailments, such as diabetes, necessitating health management.[1,3,6]

- Droppingpolypharmacy starts with duty and discussion of the patient.
- Care side members can contribution reconciling medicines, measure adherence, and aid systematically classifies drug treatmentdifficulties.
- Select pharmacotherapy that evades drug treatment problems and danger of hospitalizations. Narrowing benzodiazepines, opioids, and others are prominent.
- Shorten the routine for ambulatory patients and in long-term maintenance, when possible, to decrease hospitalizations or badevents.

TYPES OF POLYPHARMACY[5,9]

1. SAME CLASS POLYPHARMACY
2. MULTI CLASS POLYPHARMACY
3. ADJUNCTIVE POLYPHARMACY
4. AUGMENTATION POLYPHARMACY

SAME CLASS POLYPHARMACY

Usage of more than 1 medicine from the identicalclass.

MULTI CLASS POLYPHARMACY

Usageof more than one medicine from different classes for the identical symptom cluster. (ACEI + CCBI)

ADJUNCTIVE POLYPHARMACY

Usageof one medicine to treat the adverse effects of another medicine from a class. (ANTIBIOTICS + PROBIOTICS + MULTIVITAMINS)

AUGMENTATION POLYPHARMACY

Usageof one medicine at a lower dose along with another medicine from a another

class in complete therapeutic class dose for the identical symptom cluster.

REASON AND RISK OF POLYPHARMACY TO OCCUR

Polypharmacy is anpart of anxiety for aging because of numerous reasons. Aging people are at a better risk for adverse drug reactions (ADRs) because of the metabolic variations and concentrated drug consent associated with old; this risk is alsoworsened by cumulative the amount of medicines used.[6,7,8,15]

- Multiple prescribers- Patients with a prolonged disease such as diabetes regularly see experts in adding to their main care providers.
- Aging population-As the people ages, the rate of prolonged conditions growths.
- Complex drug therapies.
- Psychosocial contributions.
- Adverse drug reactions.

EVALUATION OF THE AGED PATIENT'S MULTIPLE MEDICATIONS

First, the patients' medicine must be submissive, which is a Combined Commission patient securityimportance. Integration medicines at care changes from hospital and long- term care (LTC) have been exposed to decrease errors in medicine orders and speeches clarity of variations in therapy. Following is ancalculation of adherence, withprocedures patients use to succeed medications, which frequently reveals difficulties captivating their regimen. The request of tools such as the Morisky Medication Adherence Scale has rationality in close-fitting breakdown in observance and related bar managed by a trained care side members to taking medicines.Research recurrently shows that devotion difficulties are fixed within advanced numbers of medicines and mounting doses. Deciding adherence fences in the elder adult often includes decisions about helpful means for controlling of medicine. Difficult adherence classicallycommands simplification of the routine to reduce difficulty and fences such as cost. A legalized Medication Regimen Complexity (MRC) directory was studied in patients being discharged from hospitals. The MRC was prognostic of patients' possible for ADEs and unintended hospital re-admission.[7,8,9,16]

The regimen in elder persons is separated for high-risk medicines and those interrelating with other medications and moving patient comorbidities. These gears help to classify therapy that has a high chance of ADEs likened with benefits in the elder adult is a stepwise procedure of discovering DTPs in patients taking 5 or more medicines. The glitches are defined principles of drug treatment. Recognition of

DTPs within patients' medicines is a vital starting point for improving patients' medication regimens. Lastly, the discussion should compriseancriminaltherapeutic strategy for improvingmedicines within the patients'agenda of their care goals. The plan is connected with earners and is executed and observed with taking of the patient and caregivers.[9,10]

DEPRESCRIBING MEDICATIONS[11,12,13]

HIGH-RISKMEDICATIONS	Beers Criteria, and, similarly, STOPP/ START criteria, have confirming data that prove the value of decrease of medicine that increase unwanted risk to older regimens.
STRONGLY ANTICHOLINERGIC MEDICATIONS	Older antihistamines such as diphenhydra- mine, muscle relaxants such as cyclobenzaprine, and intense bladder agents such as oxybutinyn have solid anticholinergic properties. These anticholingic medicines are usually less tolerated in aged patients.
HYPOGLYCEMICS	Episodic hypoglycemia ruins a leading source of admissions to substitute departments in older patients.Deintensification of a sugar regimen is overriding when patients are suffering episodic hypoglycemia. Sulfonylureas and short-acting insulin are among the major risk medicines.
ANTIHYPERTENSIVES	Success of goal-directed blood pressure regulator has continually proved to cutneurovascular and cardiovascular difficulties of hypertension in bulky clinical trials, even in patients of progressive age. However, patients with boundaries such as orthostasis, with connected fall risk, require careful monitoring.
NONSTEROIDAL ANTI-INFLAMMATORY DRUGS	Deprescribe (NSAIDs) toescapeadvancing the failure in kidney clearance and accumulations of medicines. In the aging, the possible for NSAIDs to move blood pressure (BP) and kidney function harmfully and to occurheart failure and gastrointestinal bleeding often compensate their benefits.

STATINS	Lipid-lowering drugsspecifically, statins are measured for stoppage in aging adults. These are naturally not high-risk medicines, in patients older than 80 years of age, cardiovascular benefit lasts to be conferred associated with those who do not take or remain on statin therapy.
HERBAL SUPPLEMENTS AND VITAMINS	Herbal supplements have feltwell-ordered clinical trials; hence, we have little proof of efficacy to defend beneficial claims or care. Herbal pharmaceuticals have possibleharmful side effects, interactions that are sick understood, and are not Food and Drug Administration (FDA) regulated. Many community-dwelling adults take every day multiple vitamin and mineral supplements.
PALLIATIVE-CARE SITUATIONS	The beginning of life-changing disease and a possibly terminal disease fetches about substantial change in each patient's strength objectives. Clinician advice given to patients and their caregivers must considerprobable beneficial and undesired things of treatments.
OPIOID	Opioid usage for chronic pain is definitelyanxious with side effects, certain of which may show deleterious, countinganbigger risk for opioid-use complaint, over-dose, myocardial infarction, and motorvehicle damage.
BENZODIAZEPINE	Benzodiazepines are the greatestusually prescribed anxiolytic medicine in elderpatients.The benefits of these medicinesprovecalmingdevastating anxiety and can advance sleep.Benzodiazepines and hypnotics that turn on the benzodiazepine gamma amino butyric acid (GABA) receptor complex are connected with a mass of tiring consequences with cognitive impairment;condense mobility, risky driving skills, failure of functional freedom, falls, fractures, and obsession.
ANTIPSYCHOTICS	Antipsychotic medicines are generally prescribed in the elder population. Older patients are 7 to18

	times furtherexpected to be given these medicines whenequated with a group of middle-aged adults.They are used when patients stancea risk of damage to themselves or others.
CHOLINESTERASE INHIBITORS	Donepezil, galantamine, and rivastigmine are cholinesterase inhibitors which all FDA approved for management of minor to moderate symptoms of Alzheimer dementia. Memantine, an methyl-D-aspartate receptor antagonist, is designated for reasonable dementia. All these mediators have been recycled off label for running of cognitive and usefulsymptoms of dementia.

CONCLUSION

Polypharmacy is collective and recurrently shows relations with problems such as falls, hospitalizations, and death, regardless of which medicines are involved. The request of guidelines such as Beers and STOPP/START criteria distinguish high-risk medicines in elderly adults and are exposed to stop ADEs and complete health care costs. Though useful, these do not completely capture completetones of clinical result making for deprescribing in separate patients. Finding a comprehensive duty and deprescribingplot is helpful in multipart and in-between care situations. Cautious vigilance for pharmacotherapy complications will permanently be important. The proofregardingpolypharmacy and high-risk medicines proposes that our elderpatient's benefit from a purposeful, lively move to rarer drugs. More often, prescribers are seeingreplacements to prescribing medicines that grasp higher dangers in old patients.

ACKNOWLEDGMENT

The authors are thankful to the VISTAS and its management for providing necessary support and facilities.

REFERENCES

1. Veehof L, Jong B, Haaijer-Ruskamp F. Polypharmacy in the elderly -a literature review. European Journal of General Practice. 2000;6(3):98-106.
2. Bulat T, Castle SC, Rutledge M, Quigley P. Clinical practice al- gorithms: medication management to reduce fall risk in the elderly-part 4, anticoagulants, anticonvulsants, anticholinergics/ bladder relaxants, and antipsychotics. J Am Acad Nurse Pract. 2008;20(4):181-190.

3. Bulat T, Castle SC, Rutledge M, Quigley P. Clinical practice al- gorithms: medication management to reduce fall risk in the elderly-part 3, benzodiazepines, cardiovascular agents, and anti- depressants. J Am Acad Nurse Pract. 2008;20(2):55-62.
4. Bulat T, Castle SC, Rutledge M, Quigley P. Clinical practice al- gorithms: medication management to reduce fall risk in the elderly-part 2, summary algorithm. J Am Acad Nurse Pract. 2008;20(1):1-4.
5. Mott S, Poole J, Kenrick M. Physical and chemical restraints in acute care: their potential impact on the rehabilitation of older people. Int J NursPract. 2005;11(3):95-101.
6. Voyer P, Martin LS. Improving geriatric mental health nursing care: making a case for going beyond psychotropic medications. Int J Ment Health Nurs. 2003;12(1):11-21.
7. Nobili A, Marengoni A, Tettamanti M, et al. Association be- tween clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. Eur J Intern Med. 2011;22(6):597-602.
8. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medica- tions and dietary supplements among older adults in the United States. JAMA. 2008;300(24):2867-2878.
9. Hanlon JT, Pieper CF, Hajjar ER, et al. Incidence and predictors of all and preventable adverse drug reactions in frail elderly per- sons after hospital stay. J Gerontol A BiolSci Med Sci. 2006;61(5): 511-515.
10. Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drug-related problems: their structure and function. DICP. 1990;24(11):1093-1097.
11. Leelakanok N, Holcombe AL, Lund BC, Gu X, Schweizer ML. Association between polypharmacy and death: a systematic re- view and meta-analysis. J Am Pharm Assoc (2003). 2017;57(6): 729-738.
12. Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ. 1997;315(7115):1096- 1099.
13. Geitona M, Latsou D, Toska A, Saridi M. Polypharmacy and adherence among diabetic patients in Greece. Consult Pharm. 2018;33(10):562-571.
14. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014; 13(1):57-65.
15. Schoonover H, Corbett CF, Weeks DL, Willson MN, Setter SM. Predicting potential postdischarge adverse drug events and 30-day unplanned hospital readmissions from medi- cation regimen complexity. J Patient Saf. 2014;10(4):186-191.
16. Bowie MW, Slattum PW. Pharmacodynamics in older adults: a review. Am J GeriatrPharmacother. 2007;5(3):263-303.